ELTX

1.4503.33%
PS

Preetam Shah

Chief Strategy & Financial Officer and Treasurer

Dr. Preetam Shah, Ph.D., M.B.A., is Chief Strategy & Financial Officer of Elicio Therapeutics, Inc. from March 24, 2025 and serves as its Treasurer since March 24, 2025. Dr. Shah served as the Chief Financial Officer at Cidara Therapeutics, Inc. since September 1, 2021 until February 24, 2025 and served as its Principal Accounting Officer since April 15, 2022 until February 24, 2025 and served as its Chief Business Officer from September 1, 2021 to August 2024. He had been Executive Vice President, Chief Financial Officer and Treasurer of Brainstorm Cell Therapeutics Inc. since September 6, 2019. Dr. Shah is an experienced healthcare finance professional with over years of diverse leadership experience in investment banking and venture capital, healthcare financial consulting, business development, sales and marketing and scientific research. Prior to BrainStorm, he served as Director of Healthcare Investment Banking at Barclays Capital Plc., since June 2016. He have experience as an investment banker advising healthcare companies on equity, debt and M&A transactions, holding senior roles at leading banks. Prior to his role at Barclays, he served as Vice President of Healthcare Investment Banking at Canaccord Genuity Inc., from July 2013 to May 2016, where he played an integral role in executing M&A transactions and equity financings for small and mid-cap publicly traded companies in the Medical Device and Diagnostics sectors. Dr. Shah founded and served as Financial Consultant of Saisarva LLC., a healthcare financial consulting firm from January 2010 to June 2013 where he completed various engagements for healthcare-focused private equity firms, hedge funds and global pharmaceutical companies. During this period, he also acted as a consultant for healthcare-focused private equity firms and hedge funds. In this capacity, he has negotiated several licensing deals with pharmaceutical companies. From October 2006 to December 2009, he served as Vice President, U.S. Operations and Investments at Reliance Capital USA Ventures LLC., an affiliate of Reliance ADA Group Companies, to head up the Company's investment operations, sales and business development activities across the U.S. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine. He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center and a M.B.A. in Finance from the Wharton School, University of Pennsylvania and a B.A. in Mathematics and in Biology from McDaniel College.

Positions